Dec 03, 2020 / 02:15PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Fantastic. Listen, guys, thank you, guys, so much for joining us. Pleasure to have Avadel management join us.
Questions and Answers:
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity ResearchGreg, there's a lot to talk about. It seems like there was a point in time where we were talking about the recruiting of your Phase III for narcolepsy with the novel formulation of sodium oxybate. That come -- that's done, you've established that once-nightly works. I think the real question for a lot of investors from here are, not so much about whether your once-nightly works, it's really all about legally and technically when and how fast you can get to market. And there's several and legal regulatory questions that come with that. So I'm going to jump right into it. But first, Greg, when do you expect to file?
Gregory J. Divis - Avadel Pharmaceuticals plc
Trustpilot
